Cargando...
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
In order to achieve higher dosages than previously used in clinical trials, we conducted a phase I trial to determine the maximum tolerated dose (MTD) for the combination of erlotinib and sirolimus for the treatments of recurrent malignant gliomas. Patients with pathologically proven World Health Or...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer US
2012
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3472078/ https://ncbi.nlm.nih.gov/pubmed/22918789 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-012-0960-y |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|